U.S. Biomarkers Market Size Worth USD 106.03 Billion by 2034 | CAGR: 15.6%

The U.S. biomarkers market size is expected to reach USD 106.03 Billion by 2034, according to a new study by Polaris Market Research. The report “US Biomarkers Market Size, Share, Trends, & Industry Analysis By Type, (Safety Biomarkers, Efficacy Biomarkers, and Validation Biomarkers), By Research Area, By Technology, By Disease Indication, By Application, and By Country – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The U.S. biomarkers market continues to grow as the use expands across hospitals, laboratories, and research institutions nationwide. Biomarkers help identify and monitor a wide range of health conditions, making it easier for healthcare professionals to deliver accurate diagnoses and track treatment progress. These tools are commonly applied in areas such as cancer, cardiovascular disease, and neurological disorders.

Questions? Request a sample or make an inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/us-biomarkers-market/request-for-sample

Industry investments and broader adoption across healthcare systems made biomarker testing a regular part of clinical and research workflows. Improvements in testing technologies and greater awareness of the benefits are further accelerating the role of biomarkers in medical practice. The contribution of biomarkers to better health outcomes and informed decision-making is becoming increasingly valuable throughout the country.

Top of FormU.S. Biomarkers Market Report Highlights

• In terms of type, the efficacy US biomarkers segment is projected to reach at a significant share by 2034. This growth is driven by the expanded use of efficacy biomarkers to evaluate drug responses during clinical trials and track therapeutic performance in real-world applications.
• Based on research area, the genomics segment held the leading market position in 2024, primarily due to its extensive application in detecting genetic variations, assessing disease susceptibility, and enabling precision medicine approaches across therapeutic areas.
• In terms of technology, the next-generation sequencing technology is anticipated to experience the most rapid market expansion during the forecast period. This accelerated growth reflects NGS's unparalleled capacity for high-throughput genomic analysis, which facilitates comprehensive biomarker discovery  
• In terms of disease indication, the cancer segment dominated the market, in 2024. This is due to rising global cancer rates and growing reliance on biomarker-based diagnostics and targeted therapies.
• In terms of application, the clinical diagnostics segment dominated the market in 2024. This is due to the growing adoption of biomarkers in routine diagnostics for cardiovascular, infectious, and oncology-related diseases.
• A few global key market players include 23andMe, Inc., Abbott Laboratories, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Charles River Laboratories International, Inc., Exact Sciences Corporation, Guardant Health, Inc., Hologic, Inc., Illumina, Inc., Johnson & Johnson Services, Inc., Laboratory Corporation of America Holdings, Meso Scale Diagnostics, LLC, PerkinElmer, Inc. (Revvity, Inc.), Quest Diagnostics Incorporated, and Thermo Fisher Scientific, Inc.

Polaris Market Research has segmented the market report on the basis of type, research area, technology, disease indication, application, and country:

By Type Outlook (Revenue, USD Billion, 2020–2034)

• Safety Biomarkers
• Efficacy Biomarkers
• Validation Biomarkers

By Research Area Outlook (Revenue, USD Billion, 2020–2034)

• Genomics
• Proteomics
• Metabolomics
• Other Research Areas

By Technology Outlook (Revenue, USD Billion, 2020–2034)

• Immunoassays
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Mass Spectrometry
• Chromatography
• Other Technologies

By Disease Indication Outlook (Revenue, USD Billion, 2020–2034)

• Cancer
• Infectious Disease
• Immunological Disorders
• Neurological Disorders
• Cardiovascular Disorders
• Other Disease Indications

By Application Outlook (Revenue, USD Billion, 2020–2034)

• Clinical Diagnostics
• Drug Discovery & Development
• Personalized Medicine
• Clinical Research
• Other Application